Search

Your search keyword '"Gangi, Alexandra"' showing total 350 results
Start Over Author "Gangi, Alexandra"
350 results on '"Gangi, Alexandra"'

51. Claudin-18

Author

Wong, Mary T., primary, Singhi, Aatur D., additional, Larson, Brent K., additional, Huynh, Carissa A. T., additional, Balzer, Bonnie L., additional, Burch, Miguel, additional, Dhall, Deepti, additional, Gangi, Alexandra, additional, Gong, Jun, additional, Guindi, Maha, additional, Hendifar, Andrew E., additional, Kim, Stacey A., additional, de Peralta-Venturina, Mariza, additional, and Waters, Kevin M., additional

Published
2022
Full Text
View/download PDF

56. Impact of site-specific metastases on survival outcomes in pancreatic adenocarcinoma (PDAC) patients: A national analysis.

Author

Nikravesh, Nima, primary, Gresham, Gillian, additional, Anderson, Eric, additional, Elmadbouh, Omer, additional, Thomassian, Shant, additional, Moshayedi, Natalie, additional, Davelaar, John, additional, Lo, Simon, additional, Gaddam, Srinivas, additional, Nissen, Nicholas, additional, Kosari, Kambiz, additional, Gangi, Alexandra, additional, Pandol, Stephen Jacob, additional, Gong, Jun, additional, Hendifar, Andrew Eugene, additional, and Osipov, Arsen, additional

Published
2022
Full Text
View/download PDF

65. A Comparison of Clinicopathologic Outcomes Across Neoadjuvant and Adjuvant Treatment Modalities in Resectable Gastric Cancer

Author

Anderson, Eric, primary, LeVee, Alexis, additional, Kim, Sungjin, additional, Atkins, Katelyn, additional, Guan, Michelle, additional, Placencio-Hickok, Veronica, additional, Moshayedi, Natalie, additional, Hendifar, Andrew, additional, Osipov, Arsen, additional, Gangi, Alexandra, additional, Burch, Miguel, additional, Waters, Kevin, additional, Cho, May, additional, Klempner, Samuel, additional, Chao, Joseph, additional, Kamrava, Mitchell, additional, and Gong, Jun, additional

Published
2021
Full Text
View/download PDF

78. Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease

Author

Karydis, Ioannis, Gangi, Alexandra, Wheater, Matthew J., Choi, Junsung, Wilson, Iain, Thomas, Kerry, Pearce, Neil, Takhar, Arjun, Gupta, Sanjay, Hardman, Danielle, Sileno, Sean, Stedman, Brian, Zager, Jonathan S., and Ottensmeier, Christian

Subjects
Adult, Male, Uveal Neoplasms, Liver Neoplasms, Middle Aged, Prognosis, chemosaturation, melphalan, Survival Rate, intrahepatic percutaneous haemoperfusion, liver metastasis, Rare Diseases, Chemotherapy, Cancer, Regional Perfusion, unresectable liver tumor, Humans, Female, uveal melanoma, Antineoplastic Agents, Alkylating, Melanoma, Research Articles, Research Article, Aged, Follow-Up Studies, Retrospective Studies
Abstract

BACKGROUND: Metastatic uveal melanoma (UM) carries a poor prognosis; liver is the most frequent and often solitary site of recurrence. Available systemic treatments have not improved outcomes. Melphalan percutaneous hepatic perfusion (M-PHP) allows selective intrahepatic delivery of high dose cytotoxic chemotherapy.METHODS: Retrospective analysis of outcomes data of UM patients receiving M-PHP at two institutions was performed. Tumor response and toxicity were evaluated using RECIST 1.1 and Common Terminology Criteria for Adverse Events (CTCAE) v4.03, respectively.RESULTS: A total of 51 patients received 134 M-PHP procedures (median of 2 M-PHPs). 25 (49%) achieved a partial (N = 22, 43.1%) or complete hepatic response (N = 3, 5.9%). In 17 (33.3%) additional patients, the disease stabilized for at least 3 months, for a hepatic disease control rate of 82.4%. After median follow-up of 367 days, median overall progression free (PFS) and hepatic progression free survival (hPFS) was 8.1 and 9.1 months, respectively and median overall survival was 15.3 months. There were no treatment related fatalities. Non-hematologic grade 3-4 events were seen in 19 (37.5%) patients and were mainly coagulopathic (N = 8) and cardiovascular (N = 9).CONCLUSIONS: M-PHP results in durable intrahepatic disease control and can form the basis for an integrated multimodality treatment approach in appropriately selected UM patients.

Published
2017

80. Dual Checkpoint Blockade in a Neuroendocrine Carcinoma With Dual PD-L1/PD-L2 Amplification and High Tumor Mutational Burden

Author

Gong, Jun, primary, Patel, Sandip, additional, Adashek, Jacob J., additional, Frishberg, David, additional, Guan, Michelle, additional, Placencio-Hickok, Veronica R., additional, Gangi, Alexandra, additional, Gresham, Gillian, additional, Tuli, Richard, additional, Chae, Young K., additional, Kurzrock, Razelle, additional, and Hendifar, Andrew E., additional

Published
2020
Full Text
View/download PDF

82. Abstract 2364: Clinical characteristics and outcomes of colorectal cancer in the ColoCare Study: Differences by age of onset

Author

Himbert, Caroline, primary, Figueiredo, Jane, additional, Huang, Lyen, additional, Gigic, Biljana, additional, Scaife, Courtney L., additional, Pickron, Bartley, additional, Lambert, Laura, additional, Cohan, Jessica, additional, Bronner, Mary, additional, Jedrzkiewicz, Jolanta, additional, Herpel, Esther, additional, Kloor, Matthias, additional, Nattenmueller, Johanna, additional, Kauczor, Hans-Ulrich, additional, Ulrich, Alexis, additional, Felder, Seth, additional, Sanchez, Julian, additional, Dessureault, Sophie, additional, Hinkle, Nathan, additional, Monroe, Justin, additional, Mutch, Matthew, additional, Bernadt, Cory, additional, Chatterjee, Deyali, additional, Sinanan, Mika, additional, Cohen, Stacey, additional, Wallin, Ulrik, additional, Reddi, Deepti, additional, Krane, Mukta, additional, Gabayan, Afshin E., additional, Hoffman, David M., additional, Nasseri, Yosef Y., additional, Decker, Robert W., additional, Zaghiyan, Karen, additional, Murrell, Zuri A., additional, Hendifar, Andrew E., additional, Gong, Jun, additional, Firoozmand, Eiman, additional, Gangi, Alexandra, additional, Moore, Beth A., additional, Cologne, Kyle G., additional, El-Masry, Maryliza, additional, Grady, William, additional, Schneider, Martin, additional, Schmit, Stephanie L., additional, Siegel, Erin, additional, Shibata, David, additional, Toriola, Adetunji, additional, Li, Christopher, additional, Ulrich, Cornelia, additional, and Hardikar, Sheetal, additional

Published
2020
Full Text
View/download PDF

83. The impact of neoadjuvant and/or adjuvant treatment modalities in resectable gastric cancer (rGC).

Author

Ng, Camille, primary, Kim, Sungjin, additional, Guan, Michelle, additional, Hendifar, Andrew Eugene, additional, Kim, Haesoo, additional, Liu, Jar-Yee, additional, Mehta, Sejal, additional, Placencio-Hickok, Veronica, additional, Gangi, Alexandra, additional, Klempner, Samuel J, additional, Burch, Miguel, additional, Chao, Joseph, additional, Cho, May Thet, additional, Kamrava, Mitchell, additional, Atkins, Katelyn Mae, additional, and Gong, Jun, additional

Published
2020
Full Text
View/download PDF

84. The Role of Palliative Surgery for Malignant Bowel Obstruction and Perforation in Advanced Microsatellite Instability-High Colorectal Carcinoma in the Era of Immunotherapy: Case Report

Author

Judge, Sean J., primary, Ji, Jingran, additional, Liu, James, additional, Kaur, Manmeet, additional, Kim, Edward, additional, Gong, Jun, additional, Tam, Kit W., additional, Kirane, Amanda R., additional, Gholami, Sepideh, additional, Canter, Robert J., additional, Bold, Richard J., additional, Gangi, Alexandra, additional, Fakih, Marwan, additional, and Cho, May, additional

Published
2020
Full Text
View/download PDF

85. Baseline features predicting receipt of chemotherapy in metastatic esophageal cancer: A National Cancer Database analysis of 12,370 patients.

Author

Manguso, Nicholas, primary, Kim, Sungjin, additional, Hendifar, Andrew Eugene, additional, Klempner, Samuel J., additional, Chao, Joseph, additional, Guan, Michelle, additional, Placencio-Hickok, Veronica, additional, Kim, Haesoo, additional, Liu, Jar-Yee, additional, Burch, Miguel, additional, Gangi, Alexandra, additional, Atkins, Katelyn Mae, additional, Kamrava, Mitchell, additional, and Gong, Jun, additional

Published
2020
Full Text
View/download PDF

87. Impact of palliative care in patients with metastatic esophageal cancer declining chemotherapy.

Author

Manguso, Nicholas, primary, Kim, Sungjin, additional, Guan, Michelle, additional, Placencio-Hickok, Veronica, additional, Kim, Haesoo, additional, Liu, Jar-Yee, additional, Hendifar, Andrew Eugene, additional, Klempner, Samuel J., additional, Burch, Miguel, additional, Gangi, Alexandra, additional, Chao, Joseph, additional, Kamrava, Mitchell, additional, Atkins, Katelyn Mae, additional, and Gong, Jun, additional

Published
2020
Full Text
View/download PDF

96. Neoadjuvant chemotherapy and surgical management of the axilla in breast cancer: a review of current data

Author

Manguso, Nicholas, Gangi, Alexandra, and Giuliano, Armando E.

Subjects
Excision (Surgery) -- Methods -- Patient outcomes, Precision medicine -- Research, Chemotherapy -- Methods -- Patient outcomes, Cancer research, Breast cancer -- Care and treatment, Health
Abstract

Neoadjuvant chemotherapy has become the standard of care for patients with locally advanced breast cancer, large tumors, certain biologic subtypes of breast cancer, or locally inoperable disease, and for patients who desire breast conservation. It has the advantage of downstaging the tumor, thereby allowing for conversion from mastectomy to breast conservation, and perhaps decreasing the need for axillary lymph node dissection (ALND). In the past, axillary management involved complete ALND for all patients presenting with breast cancer and involved nodes. With neoadjuvant chemotherapy, some patients exhibit a complete clinical axillary response, which may make them candidates for sentinel lymph node biopsy (SNLB) rather than ALND, with its associated morbidities. While there is widespread use of SLNB in the treatment of breast cancer, its use following neoadjuvant chemotherapy remains widely debated., Introduction Surgical management of the axilla in breast cancer has evolved greatly in the last 20 years. Sentinel lymph node biopsy (SLNB), which was first investigated in the early 1990s, [...]

Published
2015

98. Enhancing Lymph Node Yield in Gastric Cancer Resection: Impact of Back Table Dissection on Number of Lymph Node Examined

Author

Wong, Harry J, Rawal, Rushil, Tseng, Joshua, Phillips, Edward, Gangi, Alexandra, and Burch, Miguel

Abstract

Introduction During gastric cancer resection, back table dissection (BTD) involves examination and separation of lymph node (LN) packets from the surgical specimen based on LN stations, which are sent to pathology as separately labeled specimens. With potential impact on clinical outcomes, we aimed to explore how BTD affects number of LNs examined.Methods A retrospective review of a gastric cancer database was performed, including all cases of gastrectomy with D2 lymphadenectomy from January 2009 to March 2022. Back table dissection and conventional groups were compared using Mann-Whitney U and Fisher’s exact tests. Multiple linear regression modeling was used to identify potential predictors of number of LN examined.Results A total of 174 patients were identified: 39 (22%) BTD and 135 (78%) conventional. More patients in the BTD group underwent neoadjuvant chemotherapy (62% vs 29%, P< .05). Compared to the conventional group, the BTD group had a greater number of LNs examined (42 [26-59] vs 21[15-33], median [IQR], P< .001), lower LN positivity ratio (.01 vs .07, P= .013), and greater number of LNs in patients with BMI >35 (32.5[27.5-39] vs 22[13-27], P= .041). A multiple linear regression model controlling for age, BMI, preoperative N stage, neoadjuvant chemotherapy, surgeon experience, and operative approach identified BTD as a significant positive predictor of number of LN examined (β = 19.7, P= .001).Conclusion Back table dissection resulted in improved LN yield during gastric cancer resection. As a simple technical addition, BTD helps enhance pathology examination and improve surgeon awareness, which may ultimately translate to improve oncologic outcomes.

Published
2024
Full Text
View/download PDF

99. The Chicago Consensus on Peritoneal Surface Malignancies: Management of Appendiceal Neoplasms.

Author

Chicago Consensus Working Group, Schuitevoerder, Darryl, Plana, Alejandro, Izquierdo, Francisco J., Votanopoulos, Konstantinos I., Cusack, James C., Bijelic, Lana, Cho, Clifford S., Gangi, Alexandra, Gilbert, Erin W., Goodman, Martin D., Govindarajan, Anand, Gushchin, Vadim, Ihemelandu, Chukwuemeka, Kelly, Kaitlyn J., Merkow, Ryan P., Pappas, Sam G., Abbott, Daniel E., Ahrendt, Steven A., and Al-kasspooles, Mazin

Abstract

The Chicago Consensus Working Group provides multidisciplinary recommendations for the management of appendiceal neoplasms specifically related to the management of peritoneal surface malignancies. These guidelines are developed with input from leading experts including surgical oncologists, medical oncologists, pathologists, radiologists, palliative care physicians, and pharmacists. These guidelines recognize and address the emerging need for increased awareness in the appropriate management of peritoneal surface disease. They are not intended to replace the quest for higher levels of evidence. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

100. The Chicago Consensus on peritoneal surface malignancies: Management of appendiceal neoplasms.

Author

Schuitevoerder, Darryl, Plana, Alejandro, Izquierdo, Francisco J., Votanopoulos, Konstantinos I., Cusack, James C., Bijelic, Lana, Cho, Clifford S., Gangi, Alexandra, Gilbert, Erin W., Goodman, Martin D., Govindarajan, Anand, Gushchin, Vadim, Ihemelandu, Chukwuemeka, Kelly, Kaitlyn J., Merkow, Ryan P., Pappas, Sam G., Abbott, Daniel E., Ahrendt, Steven A., Al‐Kasspooles, Mazin, and Alpert, Lindsay

Subjects
TUMORS, CANCER, PALLIATIVE treatment, PHYSICIANS, PATHOLOGISTS, RESEARCH funding
Abstract

The Chicago Consensus Working Group provides multidisciplinary recommendations for the management of appendiceal neoplasms specifically related to the management of peritoneal surface malignancies. These guidelines are developed with input from leading experts, including surgical oncologists, medical oncologists, pathologists, radiologists, palliative care physicians, and pharmacists. These guidelines recognize and address the emerging need for increased awareness in the appropriate management of peritoneal surface disease. They are not intended to replace the quest for higher levels of evidence. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results